Incidence, risk factors and outcomes of de novo malignancies post liver transplantation.

PubWeight™: 0.78‹?›

🔗 View Article (PMID 27134701)

Published in World J Hepatol on April 28, 2016


Pavan Kedar Mukthinuthalapati1, Raghavender Gotur1, Marwan Ghabril1

Author Affiliations

1: Pavan Kedar Mukthinuthalapati, Raghavender Gotur, Marwan Ghabril, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202, United States.

Articles citing this

Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo. J Korean Med Sci (2017) 0.75

Articles cited by this

(truncated to the top 100)

The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39

High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc (2006) 8.78

Skin cancers after organ transplantation. N Engl J Med (2003) 6.65

A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res (2003) 5.04

Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99

Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 3.93

Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A (1996) 3.38

Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer (2007) 3.36

Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 2.98

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol (2010) 2.69

Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer (2003) 2.64

Prevalence, incidence and persistence of EB virus antibody in young adults. N Engl J Med (1970) 2.45

Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science (2005) 2.31

Increased cancer risk after liver transplantation: a population-based study. J Hepatol (2001) 2.25

Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl (2002) 2.00

Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol (2005) 1.99

Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl (2008) 1.97

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation (2005) 1.94

Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer (1993) 1.86

Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl (2008) 1.78

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68

Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant (2010) 1.64

Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl (2010) 1.59

Risk factors for cancer in renal transplant recipients. Transplantation (1999) 1.54

Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. Liver Transpl (2011) 1.54

Human herpesvirus 8 epidemiology: what we do and do not know. AIDS (2003) 1.49

Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol (2009) 1.47

Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology (1999) 1.45

Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl (2001) 1.40

Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis (1995) 1.39

Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant (2007) 1.37

Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol (2001) 1.35

Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant (2005) 1.33

Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol (2009) 1.28

Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation (1998) 1.28

Post-transplant lymphoproliferative disorders. Oncologist (2006) 1.27

De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation (2009) 1.25

Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin Cancer Res (2011) 1.25

Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation (2000) 1.24

mTOR, cancer and transplantation. Am J Transplant (2008) 1.24

Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl (2009) 1.22

Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol (2010) 1.22

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg (2008) 1.22

Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant (2006) 1.20

Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology (2009) 1.18

Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther (2012) 1.17

Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation (1996) 1.14

Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation (2003) 1.14

Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int (2010) 1.14

Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant (2003) 1.13

Cancer and viral infections in immunocompromised individuals. Int J Cancer (2009) 1.12

A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening. J Gastrointest Surg (2007) 1.12

CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol (2007) 1.10

Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. Arch Dermatol (2010) 1.09

De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant (2004) 1.09

De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl (2005) 1.07

De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer (1997) 1.06

Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation (2010) 1.06

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06

Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation (2005) 1.05

Smoking and cancer. Am J Med (1992) 1.02

De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. Transplant Proc (2012) 1.01

Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis (2009) 1.01

Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). Transplantation (1999) 1.00

De novo tumors after liver transplantation: a single-institution experience. Liver Transpl (2002) 1.00

Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol (2013) 1.00

Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol (2005) 0.99

De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant (2006) 0.99

Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. Am J Gastroenterol (2007) 0.99

Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer (1994) 0.98

Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl (2001) 0.98

Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg (2004) 0.97

Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer (1998) 0.97

Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl (2002) 0.97

Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol (2007) 0.95

Non-lymphoid cancer after liver transplantation. Hepatogastroenterology (1997) 0.94

Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum (1993) 0.94

Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. Transpl Int (2013) 0.94

Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant (2009) 0.93

Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. Am J Transplant (2012) 0.93

De novo malignancy post-liver transplantation: a single center, population controlled study. Clin Transplant (2013) 0.91

Organ transplantation and skin cancer: basic problems and new perspectives. Exp Dermatol (2010) 0.90

De novo tumors after orthotopic liver transplantation. Transplant Proc (2002) 0.90

Incidence and outcome of de novo malignancies after liver transplantation. Transplant Proc (1999) 0.89

Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report. Clin Transplant (2009) 0.89

De novo malignancies after organ transplantation: focus on viral infections. Curr Mol Med (2013) 0.89

Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. Am J Transplant (2007) 0.89

De novo malignancies following liver transplantation: results from a multicentric study in central and southern Italy, 1990-2008. Transplant Proc (2013) 0.88

De novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population. Transplant Proc (2005) 0.88

Indicators of genetic damage in alcoholics: reversibility after alcohol abstinence. Hepatogastroenterology (1999) 0.88

Indications and management of everolimus after liver transplantation. Transplant Proc (2009) 0.88

Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl (2005) 0.88

Post-transplant lymphoproliferative disorder after pediatric liver transplantation: characteristics and outcome. Pediatr Transplant (2008) 0.87

Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation (2002) 0.85

Alcohol abuse and de novo tumors in liver transplantation. Transplant Proc (2009) 0.85

Relation between HLA antigens and skin cancer in renal transplant recipients in Queensland, Australia. J Invest Dermatol (1997) 0.85

De novo cancer-related death in Australian liver and cardiothoracic transplant recipients. Am J Transplant (2013) 0.85

Smoking-related morbidity and mortality following liver transplantation. Liver Transpl (2008) 0.84

Malignancy after liver transplantation: cumulative risk for development. Transplant Proc (2009) 0.83

Cancer in the immunosuppressed organ recipient. Transplant Proc (1991) 0.83